Intrinsic Value

The intrinsic value of Orchestra Biomed Holdings Inc (OBIO) under the Base Case is 1.43 USD per share. Compared with the current market price of 5.73 USD, the stock appears Overvalued by 75% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

OBIO Intrinsic Value
$1.43
Overvaluation 75%
Intrinsic Value
Price $5.73
Alert me when OBIO is below its intrinsic value
Today $1.14 · 80.1% below the current price

OBIO is cheaper than usual. Still overvalued, but less so than on 89% of days in the past 5 years.

Alternatives to OBIO

Fundamental Analysis

What Orchestra Biomed Does

Health Care

Orchestra BioMed is a cardiovascular medtech company that develops treatments meant to be used by doctors during or after a procedure, rather than by patients at home. Its main ideas combine devices and drug delivery in ways designed to help treat high blood pressure and certain artery diseases. The company’s work is aimed at hospitals, interventional cardiologists, and large medical device partners that can help bring these therapies to market.

Headquarters
United States of America US
IPO date
Aug 4, 2020
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Orchestra Biomed Holdings Inc

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

OBIO Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one OBIO stock?

The intrinsic value for Orchestra Biomed Holdings Inc (OBIO) under the Base Case is 1.43 USD.

Is OBIO stock undervalued or overvalued?

Compared with the current market price of 5.73 USD, the stock appears Overvalued by 75% .

Back to Top